Rheumatoid arthritis (RA) is a systemic inflammatory disease that is associated with increased disability, morbidity, and impaired health-related quality of life with a prevalence of 0.22% in KSA. The widespread use of novel RA agents is still not achieved due to the perceived high cost of these therapies. This budget impact analysis aims to estimate the budgetary impact of adopting golimumab on Saudi Ministry of Health’s (MOH) formulary budget as a biologic treatment for Saudi RA patients, treated at the Saudi MOH facilities over a 5-year time horizon.
A budget impact model was developed in Excel to compare the total costs associated with two scenarios: the ‘World without golimumab’ (i.e. current scenario) and the ‘World with golimumab’.
The ‘World without golimumab’ scenario had a total cumulative cost of SAR 1,042 million, while the total cumulative cost of the ‘World with golimumab’ scenario was SAR 958 million ($USD 1 =3.75 SAR). The introduction of golimumab resulted in a cost saving of SAR 84 million over 5 years’ time horizon. The total drug acquisition costs were the main contributor to cost savings accounting for 96% of the savings. Golimumab had the lowest average cost per patient per year (SAR 44,255) among all SC and oral therapies, which was slightly higher than the average cost per patient per year of the lowest IV therapy, i.e. biosimilar Infliximab (SAR 39,355). In one-way sensitivity analysis, the proportion of patients on biologics, cost of adalimumab, and units of golimumab had the highest impact on the total budget savings over 5-year period.
The addition of golimumab to the drug formulary of the Saudi MOH could be a valuable option for optimal resource allocation of RA therapies as it has the potential to reduce healthcare expenditures over 5 years period.
© 2019 Published by Elsevier Inc.